Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Pilar De La Puente, PhD, Abbey Jin, Micah John Luderer, BS, MS, Barbara Muz, PhD MSc, Justin A King, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2135.

https://doi.org/10.1182/blood.V128.22.2135.2135

Published: 2016

Journal Articles

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Barbara Muz, PhD MSc, Pilar De La Puente, PhD, Justin A King, Daniel R Kohnen, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2076.

https://doi.org/10.1182/blood.V128.22.2076.2076

Published: 2016

Journal Articles

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, BPharm, Micah John Luderer, BS, MS, Jack L. Arbiser, MD, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2978.

https://doi.org/10.1182/blood.V126.23.2978.2978

Published: 2015

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Tirapazamine As a Strategy to Overcome Hypoxia-Induced Drug Resistance in Multiple Myeloma

Barbara Muz, PhDMSc, Pilar De La Puente, PhD, Micah John Luderer, BS, MS, Farideh Ordikhani, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 4436.

https://doi.org/10.1182/blood.V126.23.4436.4436

Published: 2015

Journal Articles

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

Barbara Muz, PhDMSc, Joseph Abraham, Feda Azab, BPharm, Pilar De La Puente, PhD, Nicholas Potter, Benjamin Minch, Farideh Ordikhani, Noha Salama, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 1286.

https://doi.org/10.1182/blood.V126.23.1286.1286

Published: 2015

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Justin King, Micah John Luderer, BS, MS, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2985.

https://doi.org/10.1182/blood.V126.23.2985.2985

Published: 2015

Journal Articles

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Yosef Landesman, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3017.

https://doi.org/10.1182/blood.V126.23.3017.3017

Published: 2015

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 2069.

https://doi.org/10.1182/blood.V124.21.2069.2069

Published: 2014

Journal Articles

PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell

Barbara Muz, PhDMSc, Maurizio Buggio, PhD MSc, Feda Azab, B.Pharm, Anthony F. Trombino, PhD, Mahesh Padval, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4704.

https://doi.org/10.1182/blood.V124.21.4704.4704

Published: 2014

Journal Articles

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Pilar De La Puente, PhD, Feda Azab, B.Pharm, Barbara Muz, PhDMSc, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4705.

https://doi.org/10.1182/blood.V124.21.4705.4705

Published: 2014

Journal Articles

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Scott A Rollins, PhD, Richard Alvarez, MBA, Ziad Kawar, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4758.

https://doi.org/10.1182/blood.V124.21.4758.4758

Published: 2014

Journal Articles

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

Abdel Kareem Azab, BPharm, PhD, Aneel Paulus, MDMS, Feda Azab, B.Pharm, Sharoon Akhtar, MPhil, Shireen Vali, PhD, Ansu Kumar, Neeraj Kumar Singh, Shweta Kapoor, Taher Abbasi, MS, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3024.

https://doi.org/10.1182/blood.V124.21.3024.3024

Published: 2014

Journal Articles

CD138-Independent Strategy for Detecting Residual and Circulating Myeloma Plasma Cells

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, de la Puente Pilar, PhD MSc, Jacob Paasch, BS, Justin King, Luderer Micah, Ravi Vij, MBBS, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 2077.

https://doi.org/10.1182/blood.V124.21.2077.2077

Published: 2014

Journal Articles

Hypoxia Induces Up-Regulation Of P-Glycoprotein and Promotes Resistance To Carfilzomib In Multiple Myeloma

Joseph Abraham, Salama N Noha, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 4907.

https://doi.org/10.1182/blood.V122.21.4907.4907

Published: 2013

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1947.

https://doi.org/10.1182/blood.V122.21.1947.1947

Published: 2013

Journal Articles

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 3011.

https://doi.org/10.1182/blood.V122.21.3011.3011

Published: 2013

Journal Articles

Hypoxia Induces Drug Resistance In Multiple Myeloma

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Irene M. Ghobrial, MD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 1852.

https://doi.org/10.1182/blood.V122.21.1852.1852

Published: 2013

NARROW

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Tirapazamine As a Strategy to Overcome Hypoxia-Induced Drug Resistance in Multiple Myeloma

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

CD138-Independent Strategy for Detecting Residual and Circulating Myeloma Plasma Cells

Hypoxia Induces Up-Regulation Of P-Glycoprotein and Promotes Resistance To Carfilzomib In Multiple Myeloma

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Hypoxia Induces Drug Resistance In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only